Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 3/20 | 0.43 |
| ▸ | VNN1 | O95497 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552758 | 0.95 | VNN1 (0.44) | NAMPTVNN1LMNASMN1; SMN2USP2 | |
| SCHEMBL3554481 | 0.93 | VNN1 (0.43) | NAMPTVNN1TRPV1LMNASMN1; SMN2 | |
| SCHEMBL3555172 | 0.92 | VNN1 (0.45) | NAMPTVNN1LMNASMN1; SMN2 | |
| SCHEMBL3558314 | 0.92 | VNN1 (0.48) | NAMPTVNN1LMNASMN1; SMN2USP2 | |
| SCHEMBL3551515 | 0.92 | VNN1 (0.49) | NAMPTVNN1LMNASMN1; SMN2 | |
| SCHEMBL3550414 | 0.86 | STAT3 (0.48) | NAMPTVNN1LMNASMN1; SMN2USP2 | |
| SCHEMBL3554440 | 0.86 | USP2 (0.47) | NAMPTVNN1LMNASMN1; SMN2USP2 | |
| SCHEMBL5890955 | 0.86 | HPGDS (0.47) | NAMPTVNN1LMNASMN1; SMN2USP2 | |
| SCHEMBL3557069 | 0.85 | SMN1; SMN2 (0.45) | NAMPTVNN1LMNASMN1; SMN2 | |
| SCHEMBL3559751 | 0.85 | NAMPT (0.45) | NAMPTVNN1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | claimed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | claimed |
| US-7678787-B2 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | WYETH (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287522-A1 | Pyrrolobenzodiazepine pyridine carboxamides and derivatives as follicle-stimulating hormone receptor antagonists | FSHR, GNRHR, PRLHR | NAMPT 1960/4885VNN1 4445/4885TRPV1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.